Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-2,934
Closed -$263K 371
2018
Q3
$263K Sell
2,934
-1,420
-33% -$125K 0.06% 280
2018
Q2
$346K Buy
4,354
+188
+5% +$15.6K 0.08% 238
2018
Q1
$372K Buy
4,166
+2,171
+109% +$208K 0.09% 218
2017
Q4
$208K Sell
1,995
-484
-20% -$54.6K 0.05% 294
2017
Q3
$361K Sell
2,479
-181
-7% -$24.7K 0.09% 210
2017
Q2
$345K Buy
2,660
+276
+12% +$33.8K 0.06% 199
2017
Q1
$297K Buy
2,384
+395
+20% +$47.3K 0.09% 220
2016
Q4
$230K Buy
1,989
+36
+2% +$4.01K 0.08% 243
2016
Q3
$204K Buy
+1,953
New +$211K 0.02% 251
2014
Q4
Sell
-2,264
Closed -$215K 310
2014
Q3
$215K Sell
2,264
-143
-6% -$12.9K 0.08% 256
2014
Q2
$207K Buy
+2,407
New +$183K 0.06% 268

Other funds holding CELG

NWAM LLC's CELG Position: Q4 2018 in Review

NWAM LLC sold out of Celgene Corp (CELG) in Q4 2018, closing a stake of 2,934 shares — an estimated $263K sold.

NWAM LLC first reported a position in CELG in Q2 2014 and held it in 11 quarters. The position peaked at $372K in Q1 2018. 1,317 funds tracked by Wall St. Rank hold CELG as of Q4 2018.

  • NWAM LLC reported no remaining Celgene Corp position as of Q4 2018 after selling out during the quarter.
  • NWAM LLC sold 2,934 Celgene Corp shares in Q4 2018, an estimated $263K.
  • NWAM LLC first reported a position in Celgene Corp in Q2 2014 and held it in 11 quarters.
  • NWAM LLC's Celgene Corp position peaked at $372K in Q1 2018.
  • 1,317 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2018.

Based on NWAM LLC's 13F filing for Q4 2018, filed 30 Jan 2019.